Histone Acetyltransferases as Therapeutic Targets in Cancer

Histone acetyltransferase (HAT) inhibitors have potential to target oncogenic transcription networks. Recently, high-potency catalytic and allosteric HAT inhibitors have entered clinical trials. We trace the biological rationale and medicinal chemistry innovations that have allowed for clinical implementation of this emerging drug class. Emphasis is placed on therapeutic principles, including biomarkers that enable exploitation of synthetic lethality in the case of CBP/p300 class, as well as chromosomal amplifications that cause KAT6A overexpression. Structure-based design has enabled modern inhibitors to evolve beyond cofactor mimics to effectively and selectively target cofactor pockets and maintain physiochemical properties for in vivo applications. We highlight emerging areas including targeting noncanonical HATs such as HAT1 to exploit replication stress and the development of heterobifunctional molecules that reposition HATs within their native chromatin environment to engineer desired transcriptional outputs. HAT inhibitors hold promise as monotherapies and in combination with other drug classes to target oncogenic transcription in cancers.

Authors

Institutions

Publication Details

Journal
Annual Review of Cancer Biology
Published
2026-11-18
DOI
https://doi.org/10.1146/annurev-cancerbio-062325-060606
Primary Topic
Histone Deacetylase Inhibitors Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Histone Acetyltransferases as Therapeutic Targets in Cancer

Joshua James Gruber, Andrew M. Lipchik
Annual Review of Cancer Biology
Histone Deacetylase Inhibitors Research
article

Histone Acetyltransferases as Therapeutic Targets in Cancer

Joshua James Gruber, Andrew M. Lipchik
article en

Abstract

Histone acetyltransferase (HAT) inhibitors have potential to target oncogenic transcription networks. Recently, high-potency catalytic and allosteric HAT inhibitors have entered clinical trials. We trace the biological rationale and medicinal chemistry innovations that have allowed for clinical implementation of this emerging drug class. Emphasis is placed on therapeutic principles, including biomarkers that enable exploitation of synthetic lethality in the case of CBP/p300 class, as well as chromosomal amplifications that cause KAT6A overexpression. Structure-based design has enabled modern inhibitors to evolve beyond cofactor mimics to effectively and selectively target cofactor pockets and maintain physiochemical properties for in vivo applications. We highlight emerging areas including targeting noncanonical HATs such as HAT1 to exploit replication stress and the development of heterobifunctional molecules that reposition HATs within their native chromatin environment to engineer desired transcriptional outputs. HAT inhibitors hold promise as monotherapies and in combination with other drug classes to target oncogenic transcription in cancers.

Annual Review of Cancer Biology
Eugene Applebaum College of Pharmacy and Health Sciences (US), Wayne State University (US), Southwestern Medical Center (US), The University of Texas Southwestern Medical Center (US)
Good health and well-being
Histone Deacetylase Inhibitors Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon